Efficacy and Safety of Oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus. A 52-week randomised, double-blind, active- and placebo-controlled trial
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 21 Nov 2017
At a glance
- Drugs Semaglutide (Primary) ; Liraglutide; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms PIONEER 4
- Sponsors Novo Nordisk
- 21 Nov 2017 According to a Novo Nordisk media release, the trial is expected to be completed in 2018.
- 01 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated